DORPHAN S.A. IS A DRUG DISCOVERY AND DEVELOPMENT COMPANY COMMITTED TO THE DEVELOPMENT OF INNOVATIVE THERAPEUTICS FOR THE TREATMENT OF RARE AND DEVASTATING LYSOSOMAL STORAGE DISEASES WITH HIGH UNMET MEDICAL NEED
Lysosomal storage diseases are a group of inherited metabolic disorders caused by the deficiency of lysosomal functions, in most cases due to genetic defects in the lysosomal enzymes responsible for the elimination of cellular constituents. In patients affected by lysosomal storage diseases the accumulation over time of a variety of substrates in multiple tissues and organs causes irreversible damages.
Our mission is to develop innovative therapies, including pharmacological chaperones, with the objective to rescue lysosomal enzyme function and improve patients’ life.
Company Details
- Founded
- 2011
- Address
- Epfl Science Park, Lausanne,vd 1005,switzerland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- sanorphan.com
- HQ
- Lausanne, VD
Dorphan Sa Questions
Dorphan Sa's website is sanorphan.com
Dorphan Sa's LinkedIn profile is https://ch.linkedin.com/company/sanorphan-sa
Dorphan Sa's industry is
Pharmaceutical Manufacturing
Dorphan Sa's top competitors are
Csl Vifor,
Eit Health,
Pharma Jobs Post,
Haya Therapeutics,
Corden Pharma - A Full-Service Cdmo,
Fifty Years,
Orphan Now,
Emovo Care,
Novigenix Sa,
Labatec Pharma Sa.
Dorphan Sa's categories are Pharmaceutical Manufacturing
Dorphan Sa's founding year is 2011
